Consun Pharmaceutical Group Ltd

Chart & Performance

D1W1MN

P/E

7.73

P/S

2.34

EPS

0.94

Div Yield, %

5.06%

Shrs. gr., 5y

-1.86%

Rev. gr., 5y

7.03%

Revenues

2.59b

+10.71%

Net income

785m

+14.88%

CFO

819m

-13.58%

Dividend

Sep 05, 20240.3 HKD/sh

Profile

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

URL

http://www.chinaconsun.com/

IPO date

Dec 19, 2013

Employees

3,009

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	2,590,115 10.71%	2,339,650 14.43%	2,044,660 16.65%
Cost of revenue	1,944,777	1,788,741	1,519,481
Unusual Expense (Income)
NOPBT	645,338	550,909	525,179
NOPBT Margin	24.92%	23.55%	25.69%
Operating Taxes	77,149	62,696	108,744
Tax Rate	11.95%	11.38%	20.71%
NOPAT	568,189	488,213	416,435
Net income	784,534 14.88%	682,907 15.71%	590,172 18.32%
Dividends	(326,249)	(127,492)	(198,078)
Dividend yield	8.56%	3.97%	5.59%
Proceeds from repurchase of equity	14,202	(26,428)	(15,584)
BB yield	-0.37%	0.82%	0.44%
Debt
Debt current	507,636	454,229	602,426
Long-term debt	12,014	15,602	20,218
Deferred revenue	19,179	18,929	16,700
Other long-term liabilities
Net debt	(3,072,784)	(2,576,014)	(2,956,932)
Cash flow
Cash from operating activities	818,973	947,679	725,537
CAPEX	(52,564)	(51,589)	(98,250)
Cash from investing activities	(231,772)	(368,804)	(298,305)
Cash from financing activities	(280,100)	(342,205)	(166,659)
FCF	579,480	471,662	357,435
Balance
Cash	3,583,204	3,039,345	2,426,323
Long term investments	9,230	6,500	1,153,253
Excess cash	3,462,928	2,928,862	3,477,343
Stockholders' equity	3,983,740	3,522,178	3,004,316
Invested Capital	986,497	956,358	531,602
ROIC	58.49%	65.62%	88.90%
ROCE	14.28%	13.90%	14.57%
EV
Common stock shares outstanding	799,168	791,997	804,702
Price	4.77 17.78%	4.05 -7.95%	4.40 42.86%
Market cap	3,812,031 18.84%	3,207,588 -9.41%	3,540,689 40.66%
EV	1,031,456	925,440	876,833
EBITDA	723,427	627,264	598,168
EV/EBITDA	1.43	1.48	1.47
Interest	21,264	10,933	12,905
Interest/NOPBT	3.30%	1.98%	2.46%